<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330030</url>
  </required_header>
  <id_info>
    <org_study_id>SU-07232007-459</org_study_id>
    <secondary_id>R01DA017457</secondary_id>
    <nct_id>NCT01330030</nct_id>
    <nct_alias>NCT00218647</nct_alias>
  </id_info>
  <brief_title>Selegiline Patch for Treatment of Nicotine Dependence</brief_title>
  <official_title>Selegiline Patch for Treatment of Nicotine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of
      this study is examine whether selegiline, given in the form of a skin patch, is effective in
      stopping smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most smokers relapse following smoking cessation treatment. More effective smoking cessation
      therapies are needed to prevent the high rates of relapse. Selegiline is a selective
      inhibitor of monoamine oxidase B (MAO B) and has been used clinically in combination with
      levodopa to treat Parkinson's disease. Selegiline permits the stabilization of dopamine (DA)
      levels in the brain by preventing the rapid degradation of DA by means of MAO B and is used
      as an adjunct to levodopa therapy causing a dose-sparing effect and enhancing dopaminergic
      transmission. Selegiline's effect on MAO B and the resulting effect on brain DA has
      interesting implications for the treatment of nicotine dependence because brain DA systems
      may play a key role in the mediation of reward learning behavior. Previous research suggests
      that the brains of living smokers show a 40% decrease in the level of MAO B relative to
      nonsmokers or former smokers. The purpose of this study is examine whether selegiline,
      administered in the form of a skin patch, is effective for smoking cessation.

      Participants will be randomly assigned to one of two treatments: 1) transdermal selegiline
      patch (STS) or 2) placebo. Treatment with STS or placebo will be given for a period of 8
      weeks. Participants will be stratified by gender to evaluate the role that gender plays in
      moderating smoking cessation treatment. Study visits will take place once each week for 30 to
      45 minutes, and will include adverse events monitoring, biochemical verification of smoking
      status, and a physical exam. Follow-up visits will occur at Weeks 24 and 52 to determine
      response to treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expired-air Carbon Monoxide Confirmed Smoking Abstinence</measure>
    <time_frame>52 weeks</time_frame>
    <description>expired-air carbon monoxide confirmed smoking abstinence at 52 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Drug Selegiline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo worn 24 hours for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selegiline</intervention_name>
    <description>6mg/24 hrs for 8 weeks</description>
    <arm_group_label>Drug Selegiline</arm_group_label>
    <other_name>EMSAM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>placebo/24hrs for 8 weeks</description>
    <arm_group_label>Matching placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smokes greater than 20 cigarettes per day

        Exclusion Criteria:

          -  History of Parkinson's disease, high blood pressure, or severe liver or kidney disease

          -  Current substance abuse

          -  Mental illness

          -  Skin conditions that could interfere with patch use

          -  Using antidepressant medications (e.g., levodopa/carbidopa, methyldopa, or any MAO
             inhibitor)

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel D Killen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Fong D, Lowenthal K, Bryson SW, Killen DT, Schatzberg AF. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction. 2010 Sep;105(9):1660-8. doi: 10.1111/j.1360-0443.2010.03020.x.</citation>
    <PMID>20707784</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <results_first_submitted>March 1, 2016</results_first_submitted>
  <results_first_submitted_qc>March 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2016</results_first_posted>
  <last_update_submitted>June 29, 2016</last_update_submitted>
  <last_update_submitted_qc>June 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Joel D Killen</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The original target enrollment was 230. Over recruitment led to a study sample size =243</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Drug Selegiline</title>
          <description>6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Matching Placebo</title>
          <description>matching placebo worn 24 hours for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105">number assessed at week 52 follow-up</participants>
                <participants group_id="P2" count="105">number assessed at week 52 follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drug Selegiline</title>
          <description>6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks
Selegiline: 6mg/24 hrs for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Matching Placebo</title>
          <description>matching placebo worn 24 hours for 8 weeks
matching placebo: placebo/24hrs for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="243"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Expired-air Carbon Monoxide Confirmed Smoking Abstinence</title>
        <description>expired-air carbon monoxide confirmed smoking abstinence at 52 weeks</description>
        <time_frame>52 weeks</time_frame>
        <population>intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Drug Selegiline</title>
            <description>6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks
Selegiline: 6mg/24 hrs for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Matching Placebo</title>
            <description>matching placebo worn 24 hours for 8 weeks
matching placebo: placebo/24hrs for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Expired-air Carbon Monoxide Confirmed Smoking Abstinence</title>
          <description>expired-air carbon monoxide confirmed smoking abstinence at 52 weeks</description>
          <population>intention to treat</population>
          <units>participants not smoking</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Drug Selegiline</title>
          <description>6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks
Selegiline: 6mg/24 hrs for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Matching Placebo</title>
          <description>matching placebo worn 24 hours for 8 weeks
matching placebo: placebo/24hrs for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="121"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Lightheaded</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="121"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="57" subjects_affected="57" subjects_at_risk="121"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>racing thoughts</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="121"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="121"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="121"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Joel D Killen</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-723-5895</phone>
      <email>jkillen@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

